Topotecan for small cell lung cancer

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2008, Pages

  Wang, X S ^b   Hou, M ^b   Xue, S L ^b   Wu, Taixiang X ^a  

^a SICHUAN UNIVERSITY   (China)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

TOPOTECAN;

BIBLIOGRAPHIC DATABASE; DATA ANALYSIS; DATA EXTRACTION; DRUG EFFICACY; DRUG SAFETY; LUNG SMALL CELL CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 44949225198     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007184     Document Type: Review

References (24)

1. ACS 2006 American Cancer Society. Cancer Facts and Figures 2006. American Cancer Society 2006. Also available online 2006.
2. Adjei 1999 Adjei AA, Marks RS, Bonner JA. Current guidelines for the management of small cell lung cancer. Mayo Clin Proc 1999;74:809-16.
3. Ardizzoni 1997 Ardizzoni A, Hansen H, Dombernowsky P. Topotecan,a new active drug in the second-line treatment of small-cell lung cancer:a phase 2 study in patients with refractory and sensitive disease. J Clin Oncol 1997;15:2090-6.
4. Bahadori 2001 Bahadori HR, Green MR, Catapano CV. Synergistic interaction between topotecan and microtubule-interfering agents. Cancer Chemother Pharmacol 2001;48:188-96.
5. Centre 1998 Centre Francois Baclesse. Topotecan:An Oncologist' View. The Oncologist 1998;3:390-402.
6. CTCAE 2006 National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/reporting/ctc_v30.html 2006, accessed in 23 Dec. 2007.
7. Depierre 1997 Depierre A, von Pawel J, Hans K. Evaluation of topotecan in relapsed small cell lung cancer(SCLC):A multicentre phase 2 study. Lung Cancer 1997;18(suppl 1):35.
8. Eckardt 1996 Eckardt J, Gralla R, Palmer MC. Topotecan(T) as second line therapy in patients(Pts) with small cell lung cancer(SCLC);a phase 2 study. Ann Oncol 1996;7(suppl 5):107.
9. Egger 1997 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple,graphical test. BMJ 1997;315(7109):629-34.
10. Greco 2003 Greco FA. Topotecan as first-line therapy for small cell lung cancer. Lung Cancer 2003;41(suppl 4):S3-S9.
11. Higgins 2002 Higgins JPT, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med 2002;21(11):1539-58.
12. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. The Cochrane Library. UK: John Wiley & Sons, Ltd, 2005.
13. Jonsson 1998 Jonsson E, Fridborg H, Nygren P. Synergistic interactions of combinations of topotecan with standard drug in primary cultures of human tumor cells from patients. Eur J Clin Pharmacol 1998;54:509-14.
14. Korfel 2002 Korfel A, Oehm C, von Pawel J. Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-irradiation: A multicenter phase 2 study. Eur J Cancer 2002;38:1724-9.
15. Nagourney 2003 Nagourney RA, Sommers BL, Harper SM. Ex vivo analysis of topotecan: advancing of the application of laboratory-based clinical therapeutics. Br J Cancer 2003;89:1789-1795.
16. Okuno 2002 Okuno SH, Jett JR. Small cell lung cancer:current therapy and promising new regimens. The Oncologist 2002;7:234-8.
17. Parmar 1998 Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
18. Patrick 2000 Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, Jantien Wanders, Richard S. Kaplan, Larry Rubinstein, et al.New Guidelines to Evaluate the Response to Treatment in Solid Tumors. Journal of the National Cancer Institute 2000;92(3):205-16.
19. Perez-Soler 1996 Perez-Soler R, Glisson BS, Lee JS. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomer-ase 1 poison topotecan. J Clin Oncol 1996;14:2785- 90.
20. Schiller 2001 Schiller JH. Current standards of care in small-cell and non-small-cell lung cancer. Oncology 2001;61(suppl 1):3-13.
21. von Pawel 2003 von Pawel J. The role of topotecan in treating small cell lung cancer: second-line treatment. Lung Cancer 2003;41(suppl 4):S3-S8.
22. WHO 1979 World Health Organization. WHO handbook for reporting results of cancer treatment. Albany, N.Y. : sold by WHO Publications Centre USA: Geneva : World Health Organization, 1979.
23. Wong 2004 Wong ET, Berkenblit A. The role of topotecan in the treatment of metastases. The Oncologist 2004;9:68-79.
24. Wu 2007 Taixiang Wu, Guanjian Liu. What about the concepts, design, practice and report of allocation concealment and blinding exactly?. Chinese Journal of Evidence-Based Medicine 2007;7(3):203-7.